Biomedical chromatography : BMCAnimalsTandem Mass SpectrometryMiceJanus Kinase 2Chromatography
Validated LC-MS/MS Method for the Quantitative Determination and Pharmacokinetic Profiling of Fedratinib (TG101348), an Oral JAK2 Inhibitor, in CD1 Mice Plasma.
Rajesh Kumar Boggavarapu, Vishwottam Kandikere, Jithendra Chimakurthy
Published: 202610.1002/bmc.70285
Abstract
Fedratinib, a selective Janus kinase 2 (JAK2) inhibitor approved by the FDA for the treatment of myeloproliferative neoplasms, particularly myelofibrosis (MF), has clinical relevance. Despite this, no liquid chromatography-tandem mass spectrometry (L…
Preview only. Read the full abstract at the source